These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1664962)

  • 1. In vitro evaluation of a casomorphin related pentapeptide, a competitive mu opioid receptor antagonist.
    Davis P; Tourwe D; Delaet N; Kramer TH; Burks TF
    Proc West Pharmacol Soc; 1991; 34():429-32. PubMed ID: 1664962
    [No Abstract]   [Full Text] [Related]  

  • 2. Opioid peptides derived from pre-proenkephalin B sequence: biological evaluation in guinea pig ileum and mouse vas deferens.
    Sánchez-Blázquez P; Garzón J; Lee NM
    Proc West Pharmacol Soc; 1983; 26():85-8. PubMed ID: 6688470
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of dynorphin-selective Kappa receptors in mouse vas deferens and guinea pig ileum. Spare receptor fraction as a determinant of potency.
    Cox BM; Chavkin C
    Mol Pharmacol; 1983 Jan; 23(1):36-43. PubMed ID: 6135144
    [No Abstract]   [Full Text] [Related]  

  • 4. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of biological activities of enkephalin analogues in isolated organs.
    Friedmann T; Medzihradszky K; Kovács A; Kerecsen L; Szécsi JH; Di Gléria K; Knoll J
    Pol J Pharmacol Pharm; 1982; 34(1-3):53-61. PubMed ID: 6300815
    [No Abstract]   [Full Text] [Related]  

  • 6. Demonstration of the crucial role of the phenylalanine moiety in enkephalin analogues for differential recognition of the mu- and delta-receptors.
    Roques BP; Gacel G; Fournie-Zaluski MC; Senault B; Lecomte JM
    Eur J Pharmacol; 1979 Nov; 60(1):109-10. PubMed ID: 230063
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
    Kramer TH; Shook JE; Kazmierski W; Ayres EA; Wire WS; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1989 May; 249(2):544-51. PubMed ID: 2566679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid profiles of Cys2-containing enkephalin analogues.
    Pencheva N; Milanov P; Vezenkov L; Pajpanova T; Naydenova E
    Eur J Pharmacol; 2004 Sep; 498(1-3):249-56. PubMed ID: 15364002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo and in vitro investigation of naltrindole, a delta-opioid antagonist.
    Ayres EA; Davis P; Burks TF
    Proc West Pharmacol Soc; 1990; 33():55-63. PubMed ID: 2177196
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro profile of some opioid pentapeptide analogues.
    Shaw JS; Turnbull MJ
    Eur J Pharmacol; 1978 Jun; 49(3):313-7. PubMed ID: 658147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between circular dichroism data and biological activities of 2,5 substituted enkephalin analogues.
    Soós J; Berzétei I; Bajusz S; Rónai AZ
    Life Sci; 1980 Jul; 27(2):129-33. PubMed ID: 6249995
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of mechanisms and sites of actions of mu and delta opioid receptor activation in the canine intestine.
    Fox-Threlkeld JE; Daniel EE; Christinck F; Hruby VJ; Cipris S; Woskowska Z
    J Pharmacol Exp Ther; 1994 Feb; 268(2):689-700. PubMed ID: 8113980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (-)-N,N'-but-2-ene-1,4-diylbimorphinans.
    Schmidhammer H; Smith CF; Dalkner E; Erlach D; Heuberger M; Rollinger JM
    Pharmazie; 1991 Feb; 46(2):101-2. PubMed ID: 1649476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands.
    Kramer TH; Davis P; Hruby VJ; Burks TF; Porreca F
    J Pharmacol Exp Ther; 1993 Aug; 266(2):577-84. PubMed ID: 8394911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic evaluation of a cyclic somatostatin analog with antagonist activity at mu opioid receptors in vitro.
    Shook JE; Pelton JT; Wire WS; Hirning LD; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1987 Mar; 240(3):772-7. PubMed ID: 2882015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions.
    Shook JE; Pelton JT; Lemcke PK; Porreca F; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1987 Jul; 242(1):1-7. PubMed ID: 2886635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RX809055AX in vivo: a long lasting opioid antagonist at mu and delta receptors.
    Lemcke PK; Ayres EA; Kramer TH; Burks TF
    Proc West Pharmacol Soc; 1989; 32():173-5. PubMed ID: 2550942
    [No Abstract]   [Full Text] [Related]  

  • 19. Alpha-azido acids for direct use in solid-phase peptide synthesis.
    Tornøe CW; Davis P; Porreca F; Meldal M
    J Pept Sci; 2000 Dec; 6(12):594-602. PubMed ID: 11192239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.